Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...
Health on MSN4d
Does Adjuvant Therapy Prevent Cancer Recurrence?
"Neoadjuvant therapy” refers to supplemental cancer treatment you receive before your primary treatment. Adjuvant therapies, ...
Cure Today10d
Keytruda Plus Chemoradiotherapy May Represent New Standard of Care in Cervical Cancer Subset
Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
Merck Gets European Panel Backing for Keytruda in Two Gynecologic Cancers
Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...